Non-alcoholic fatty liver disease and pregnancy

Cover Page

Cite item

Full Text

Abstract

The issues of epidemiology, risk factors, and pathogenetic mechanisms of non-alcoholic fatty liver disease during pregnancy are considered in the review. The impact of liver steatosis and obesity on the course and outcome of pregnancy, the perinatal state of the mother and fetus are described. Fluctuations in the hormonal spectrum, an increase in body weight, which can affect the development and progression of liver steatosis, occur during pregnancy. Women of reproductive age with metabolic syndrome, obesity require a thorough examination and, if it is necessary, optimization of metabolic health before planning pregnancy. Pregnant women with liver pathology need dynamic control and prevention of disease progression and associated obstetric complications.

Full Text

Introduction

Fatty liver disease is quite common during pregnancy and occurs in two completely different conditions: non-alcoholic fatty liver disease (NAFLD) and acute fatty liver disease across pregnancy. The prevalence of NAFLD increases every year and is registered in 10–20 % of women of childbearing age [1; 2], 10–15 % of pregnant women [3], which is associated with the obesity pandemic and the increasing age of pregnant women, especially in Western countries. The number of pregnant women with fatty liver disease is expected to increase in the coming years [4]. During pregnancy, there are fluctuations in the hormonal spectrum and an increase in body weight, which can affect the development and progression of liver steatosis [5]. The issues of diagnosis and principles of correction of NAFLD in pregnant women, the features of maternity care, childbirth and the postpartum period in these women are also discussed.

Epidemiology and risk factors for NAFLD in pregnancy

Recently, there has been an increase in obstetric and perinatal pathology caused by hepatocellular insufficiency. Pathology of the hepatobiliary system occurs in women 4.7 times more often than in men, which leads to an increase in the number of pregnant women with liver diseases [6; 7]. Liver pathology is registered in 3–5 % of pregnant women and is characterized by a variety of etiological forms, which are divided into two main groups: liver damage caused by pregnancy itself (with uncontrollable vomiting of pregnancy, intrahepatic cholestasis of pregnancy, acute fatty liver disease of pregnancy, liver damage in preeclampsia, eclampsia and HELLP syndrome), and liver diseases not directly caused by pregnancy (acute diseases that developed during pregnancy and chronic diseases that preceded pregnancy, including NAFLD) [8; 9]. Over the past 10 years, there has been a trend towards an increase in the prevalence of NAFLD among women [10], as well as a sharper increase in mortality compared to men [11].

NAFLD is associated with an increase in the prevalence of risk factors in the population, such as metabolic syndrome (MS), obesity, diabetes mellitus and dyslipidemia [5]. In women, MS develops 2.4 times more often than in men [12], in women of childbearing age, MS is recorded in 7.6–15.7 % [13; 14], the increase in the prevalence of MS among pregnant women, according to some data, over a period of 1988–2015 amounted to from 3 to 42 % [15].

Recently, the problem of obesity and overweight, according to WHO, has become a pandemic of global proportions. By 2025, the number of obese people worldwide is expected to reach approximately 300 million. Obesity has a detrimental effect on every aspect of reproductive health and during pregnancy can have enormous consequences and increase the risk of obstetric pathologies such as gestational hypertension, preeclampsia, gestational diabetes and preterm birth [16–18]. For one in five women of reproductive age, obesity has a high socioeconomic cost due to increased risk of maternal and neonatal complications [19]. It has been established that gestational diabetes mellitus occurs significantly more frequently in obese pregnant women, regardless of the type of fat deposition. The visceral type of fat tissue distribution is associated with an increased risk of gestational diabetes mellitus in women with normal and excess body weight [20; 21].

Dyslipidemia is diagnosed in 40–50 % of the population and is often asymptomatic [22]. Pregnancy changes lipid parameters as early as the 12th week, causing physiological hyperlipidemia, which can affect the outcome of pregnancy [23]. According to research, all obese pregnant women in the third trimester have dyslipidemia with a predominance of the atherogenic fraction of lipoproteins and hypertriglyceridemia, 12 % have hyperfermentemia, and 52 % have signs characteristic of liver steatosis according to ultrasound data. Moreover, premature and late births were significantly more common in the group of women with obesity compared to pregnant women with normal BMI [24]. Pregnancy alters lipid parameters from the 12th week of amenorrhea and causes physiological hyperlipidemia. The lipid profile of patients may influence obstetric outcome. There is an increased risk of gestational diabetes (33 %), preeclampsia (25 %) and gestational cholestasis [25–27].

The characteristics of MS make it difficult to conduct retrospective studies to determine the contribution of each metabolic risk factor to the development of NAFLD during pregnancy. Prospective studies are needed to clarify the association between NAFLD and pregnancy-specific features and to assess the actual impact of NAFLD on pregnancy outcomes [2].

Pathogenetic mechanisms linking NAFLD and pregnancy

The pathogenesis of NAFLD is currently considered as a complex multifactorial process of a combination of adipose tissue dysfunction with hyperproduction of proinflammatory cytokines, insulin resistance, activation of lipolysis, dyslipidemia, impaired hepatic lipid clearance, oxidative stress, mitochondrial and endothelial dysfunction, and intestinal microbiota disorders [2; 14; 28–33].

There is currently no evidence that pregnancy can provoke the development of NAFLD, but it has been proven that estrogen imbalance, weight gain and insulin resistance (IR) due to pregnancy itself, as well as the result of obesity before and during pregnancy, are important in the pathogenesis of liver steatosis during pregnancy. Leptin and insulin levels directly correlate with gestational age [2; 34]. It has been established that IR in obese pregnant women is based on proinflammatory processes, since visceral adipose tissue synthesizes proinflammatory cytokines, which leads to the development of systemic inflammation and changes in endocrine and immune functions [35–37].

There is evidence that the production of proinflammatory cytokines in obese pregnant women may increase in adipose tissue, blood, placenta and mucous membranes, including the intestines, where an increase in the number of opportunistic microorganisms is recorded. Gut microbiota is involved in whole-body metabolism, influencing energy balance, glucose metabolism, and low-grade inflammation associated with obesity and associated metabolic disorders [38]. The number of microorganisms increases from the first to the third trimester of pregnancy. High concentrations of bacteroides are associated with excessive weight gain during pregnancy [39].

The mechanisms of pathogenesis of insulin resistance, endothelial dysfunction underlying the formation of placental insufficiency and preeclampsia, thrombophilia, against the background of a chronic inflammatory reaction in pregnant women with obesity have been described [37]. It has been established that clinical manifestation of previously asymptomatic NAFLD may occur during pregnancy [27].

Influence of NAFLD on the course and outcome of pregnancy

Obesity and NAFLD can affect the course of pregnancy, labor, and the postpartum period. Complications such as miscarriage, preeclampsia, premature birth, bleeding, infections are registered, and the risk of congenital anomalies and fetal death increases [14; 41–44].

A large meta-analysis involving patients of childbearing age showed an association of liver steatosis with the risk of developing miscarriage, preeclampsia and eclampsia, gestational hypertension and diabetes mellitus, premature birth, and bleeding in the postpartum period [45–48]. There is evidence that NAFLD is associated with an increased risk of low birth weight and more frequent Cesarean sections. The risk of developing preeclampsia and gestational diabetes is increased in pregnant women with NAFLD even in the absence of obesity or overweight [48]. There is also an increase in the incidence of rapid development of liver cirrhosis as an outcome of NAFLD [49] and a higher risk of developing this pathology in infants born to mothers with NAFLD [50; 51]. There is also an increase in the incidence of rapid development of liver cirrhosis as an outcome of NAFLD [49] and a higher risk of developing this pathology in infants born to mothers with NAFLD [50; 51].

The pathophysiological mechanisms of the influence of NAFLD on the perinatal state of the mother and fetus are not completely clear. There is an opinion that IR associated with NAFLD activates the sympathoadrenal and renin-angiotensin-aldosterone systems, leads to endothelial dysfunction, which can contribute to the development of hypertension [52]. The development of preeclampsia in NAFLD and obesity is associated with an imbalance of adipose tissue hormones [53–55].

Conclusions

Structural and functional changes in the liver affect the course of pregnancy and require timely adequate correction. Women of fertile age with MS and obesity require a thorough examination and, if necessary, optimization of metabolic health before the planned pregnancy.

Pregnant women with NAFLD require dynamic monitoring and prevention of disease progression and associated obstetric complications. The complex of preventive measures should include recommendations to prevent excessive weight gain during pregnancy (diet and exercise), as well as hepatotropic agents as indicated. Appropriate counseling and monitoring of patients with or at risk for hepatic steatosis during pregnancy may have significant health benefits for the mother and child.

×

About the authors

T. P. Shevlyukovа

Tyumen State Medical University

Email: bula.1977@mail.ru
ORCID iD: 0000-0002-7019-6630

DSc (Medicine), Professor of the Department of Obstetrics and Gynecology

Russian Federation, Tyumen

I. A. Bulatovа

E.A. Vagner Perm State Medical University

Author for correspondence.
Email: bula.1977@mail.ru
ORCID iD: 0000-0002-7802-4796

DSc (Medicine), Professor of the Department of Faculty Therapy № 2, Occupational Pathology and Clinical Laboratory Diagnostics, Head of the Department of Normal Physiology

Russian Federation, Perm

References

  1. Younossi Z.M., Koenig A.B., Abdelatif D. et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016; 64: 73–84.
  2. Hershman M., Mei R., Kushner T. Implications of nonalcoholic fatty liver disease on pregnancy and maternal and child outcomes. Gastroenterol Hepatol (N Y) 2019; 15: 221–228.
  3. Yki-Jarvinen H. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diabetes Endocrinol. 2014; 2: 901–10.
  4. Azzaroli F., Mazzella G., Marchesini G. et al. Fatty liver in pregnancy: a narrative review of two distinct conditions. Expert Rev Gastroenterol Hepatol. 2020; 14 (2): 127–135.
  5. Ливзан М.А., Сыровенко М.И., Кролевец Т.С. Неалкогольная жировая болезнь печени и женское здоровье. РМЖ. Медицинское обозрение 2023; 7 (5): 310–317. doi: 10.32364/2587-6821-2023-7-5-9 / Livzan M.A., Syrovenko M.I., Krolevets T.S. Non-alcoholic fatty liver disease and women's health. breast cancer. Medical Review 2023; 7 (5): 310–317. doi: 10.32364/2587-6821-2023-7-5-9 (in Russian).
  6. Новрузова Д.Р., Соснова Е.А. Особенности состояния гепатобилиарной системы при физиологическом течении беременности и на фоне приема лекарственных препаратов. Архив акушерства и гинекологии им. В.Ф. Снегирева 2018; 2 (5): 60–64. doi: 10.18821/2313-8726-2018-5-2-60-64 / Novruzova D.R., Sosnova E.A. Features of the state of the hepatobiliary system during the physiological course of pregnancy and against the background of taking medications. V.F. Snegirev Archive of Obstetrics and Gy-necology 2018; 2 (5): 60–64. doi: 10.18821/2313-8726-2018-5-2-60-64 (in Russian).
  7. Allen A.M., Kim W.R., Larson J.J. et al. The epidemiology of liver diseases unique to pregnancy in a US Community: a population-based study. Clin. Gastroenterol. Hepatol. 2016; 14 (2): 287–94.e2. DOI: 10.1016/j. cgh.2015.08.022.
  8. Григоренко Е.И., Максимова Е.В., Кляритская И.Л. Заболевания печени у беременных. КТЖ 2020; 2: 21–31 / Grigorenko E.I., Maksimova E.V., Klaritskaya I.L. Liver diseases in pregnant women. KTZ 2020; 2: 21–31 (in Russian).
  9. Пальгова Л.К., Мозговая Е.В., Жесткова Н.В. и соавт. Болезни печени и беременность. Анализ актуальных клинических рекомендаций и соб-ственный опыт. Часть первая. Болезни печени, связанные с беременностью. Экспериментальная и клиническая гастроэнтерология 2018; 151 (3): 105–114 / Palgova L.K., Mozgovaya E.V., Zhestkova N.V. at al. Liver disease and pregnancy. Analysis of current clinical recommendations and own experience. Part one. Liver diseases associated with pregnancy. Experimental and Clinical Gastroenterology 2018; 151 (3): 105–114 (in Russian).
  10. Arshad T., Golabi P., Paik J. et al. Prevalence of nonalcoholic fatty liver disease in the female population. Hepatol Commun. 2019; 3 (1): 74–83. doi: 10.1002/hep4.1285
  11. Paik J.M., Henry L., De Avila L. et al. Mortality related to nonalcoholic fatty liver disease is increasing in the United States. Hepatol Commun. 2019: 3 (11): 1459–1471. doi: 10.1002/hep4.1419
  12. Lee C., Tsenkova V.K., Boylan J.M. et al. Gender diff erences in the pathways from childhood disadvantage to metabolic syndrome in adulthood: An examination of health lifestyles. SSM Popul Health. 2018; 4: 216–224.
  13. Szostak-Węgierek D., Waśkiewicz A., Piotrowski W. et al. Metabolic syndrome and its components in Polish women of childbearing age: a nationwide study [published correction appears in BMC Public Health. 2017; 18 (1): 15.
  14. Иванюк Е.С., Саликова С.П., Ива-нюк Г.Ю. Метаболический синдром и беременность. Есть ли гастроэнтерологический след? Экспериментальная и клиническая гастроэнтерология 2020; 183 (11): 74–79. doi: 10.31146/1682-8658-ecg-183-11-74-79 / Ivanyuk E.S., Salikova S.P., Ivanyuk G.Y. Metabolic syndrome and pregnancy. Is there a gastroenterological trace? Experimental and clinical gastroenterology 2020; 183 (11): 74–79. doi: 10.31146/1682-8658-ecg-183-11-74-79 (in Russian).
  15. Tavares H.P., Arantes M.A., Tavares S.B. et al. Metabolic Syndrome and Pregnancy, Its Prevalence, Obstetrical and New-borns Complications. Open Journal of Obstetrics and Gynecology 2015; 5 (11) 618–625.
  16. Poston L., Harthoorn L.F., van der Beek E.M. Obesity in pregnancy: implica-tions for the mother and lifelong health of the child. A consensus statement. Pediatr Res 2011; 69 (2): 175–180.
  17. Hamsir F., As’ad S., Tahir A.M. et al. Macro- and micronutrient of junk food and preeclampsia on pregnant women. Open Access Maced J Med Sci 2022; 10: 1–6.
  18. Gete D.G., Waller M., Mishra G.D. Efects of maternal diets on preterm birth and low birth weight: a systematic review. Br J Nutr 2020; 123 (4): 446–461. doi: 10.1017/S0007114519002897
  19. Jarvie E., Hauguel-de-Mouzon S., Nelson S.M. et al. Lipotoxity in obese pregnancy outcome and obesity in the offspring. Clin. Sci. (Lond). 2010; 119 (3): 123–9. doi: 10.1042/CS20090640
  20. Чабанова Н.Б., Василькова Т.Н., Шевлюкова Т.П. Значение висцерального ожирения в увеличении риска гестационного сахарного диабета у женщин в зависимости от индекса массы тела. Университетская медицина Ура-ла 2018; 4 (15): 44–45 / Chabanova N.B., Vasilkova T.N., Shevlyuko¬va T.P. The importance of visceral obesity in in-creasing the risk of gestational diabetes mellitus in women depending on body mass index. Ural University Medicine 2018; 4 (15): 44–45 (in Russian).
  21. Чабанова Н.Б., Василькова Т.Н., Полякова В.А., Шевлюкова Т.П. Оценка характера жироотлажения в динамике гестационного процесса по данным ультразвукового исследования. Российский электронный журнал лучевой диагностики 2018; 1 (8): 129–136 / Chabanova N.B., Vasilkova T.N., Polya-kova V.A., Shevlyakova T.P. Assessment of the nature of fat deposition in the dynamics of the gestational process according to ultrasound data. Russian Electronic Journal of Radiation Diagnostics 2018; 1 (8): 129–136 (in Russian).
  22. Haslam D.E., Peloso G.M., Herman M.A. et al. Beverage consumption and longitudinal changes in lipoprotein concentrations and incident dyslipidemia in US adults: the Framingham heart study. JAHA 2020; 9 (5): e014083
  23. Jin W.-Y., Lin S.-L., Hou R.-L., Chen X.-Y., Han T., Jin Y. et al. Associations between maternal lipid profle and pregnancy complications and perinatal outcomes: a population-based study from China. BMC Pregnancy Childbirth 2016; 16 (1): 60.
  24. Макаров И.О., Боровкова Е.И., Казаков Р.Д. Распространенность неалкогольной жировой болезни печени у беременных с ожирением. Акушерство. Гинекология. Репродукция 2012; 4 (6): 18–21 / Makarov I.O., Borovkova E.I., Kazakov R.D. Prevalence of non-alcoholic fatty liver disease in obese pregnant women. Obstetrics. Gynecology. Reproduction 2012; 4 (6): 18–21 (in Russian).
  25. El Jamaly H., Eslick G.D., Weltman M. Systematic review with meta-analysis: non-alcoholic fatty liver disease and the association with pregnancy outcomes. Clin Mol Hepatol 2022; 28 (1): 52–66.
  26. Cordivani J., Clotilde L., Michel B. et al. Non-alcoholic steatohepatitis in pregnancy: a case report. Bull Natl Res 2023; 136. doi: 10.1186/s42269-023-01110-0
  27. Sarkar M., Grab J., Dodge J.L. et al. Non-alcoholic fatty liver disease in pregnancy is associated with adverse maternal and perinatal outcomes. J Hepatol 2020; 73 (3): 516–522.
  28. Булатова И.А., Щёкотова А.П., Карлышева К.Н. и соавт. Лептин, провоспалительные цитокины и функциональные печеночные тесты при метаболическом синдроме в сочетании с жировым поражением печени. Пермский медицинский журнал 2014; 2 (31): 86–91 / Bulatova I.A., Shchekotova A.P., Karlysheva K.N. et al. Leptin, proinflammatory cytokines and functional liver tests in metabolic syndrome in com-bination with fatty liver disease. Perm Medical Journal 2014; 2 (31): 86–91 (in Russian).
  29. Щёкотова А.П., Кривцов А.В., Булатова И.А., Загородских Е.Б. Энлотелиальная дисфункция и полиморфизм гена эндотелиальной синтазы оксида азота (NOS3) при хронических заболеваниях печени. Современные проблемы науки и образования 2012; 2: 109 / Shchekotova A.P., Krivtsov A.V., Bulatova I.A., Zagorodskikh E.B. Endo-thelial dysfunction and polymorphism of the endothelial nitric oxide synthase (NOS3) gene in chronic liver diseases. Modern problems of science and education 2012; 2: 109 (in Russian).
  30. Щёкотова А.П., Булатова И.А., Падучева С.В. Клинико-диагностические проблемы фиброза/цирроза печени. Пермский медицинский журнал 2018; 5 (35): 98–107 / Shchekotova A.P., Bulatova I.A., Paducheva S.V. Clinical and diagnostic problems of liver fibrosis/cirrhosis. Perm Medical Journal 2018; 5 (35): 98–107 (in Russian).
  31. Булатова И.А., Щёкотова А.П., Суздальцева К.Н. и соавт. Супероксид-дисмутаза глутатионредуктаза при хроническом гепатите С и неалкогольной жировой болезни печени. Фундаментальные исследования 2014; 7: 455–459 / Bulatova I.A., Shchekotova A.P., Suzdaltseva K.N. et al. Su-peroxide dismutase glutathione reductase in chronic hepatitis C and non-alcoholic fatty liver disease. Fundamental research 2014; 7: 455–459 (in Russian).
  32. Щёкотова А.П., Булатова И.А. Роль васкулоэндотелиального фактора роста и его гена в патогенезе гепатобилиарной патологии. Пермский медицинский журнал 2020; 4 (37): 36–45 / Shchekotova A.P., Bulatova I.A. The role of vascular endothelial growth factor and its gene in the pathogenesis of hepatobiliary pathology. Perm Medical Journal 2020; 4 (37): 36–45 (in Russian).
  33. Булатова И.А., Мифтахова А.М., Гуляева И.Л. Выраженность воспали-тельного синдрома и эндотелиальной дисфункции при стеатозе и фиброзе печени. Пермский медицинский журнал 2021; 4 (38): 54–62 / Bulatova I.A., Miftakhova A.M., Gulyaeva I.L. The severity of inflammatory syndrome and endothelial dysfunction in steatosis and liver fibrosis. Perm Medical Journal 2021; 4 (38): 54–62 (in Russian).
  34. Estes C., Razavi H., Loomba R. et al. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an ex-ponential increase in burden of disease. Hepatology 2018; 67 (1): 123–133. doi: 10.1002/hep.29466
  35. Salem S.Y., Kessous R., Pariente G. et al. Obesity in pregnancy: whats next? Long-term cardiovascular morbidity in a follow-up period of more than a decade. Am J Obstet Gynecol 2014; 210 (1.): 45–68.
  36. Тарасенко К.В., Мамонтова Т.В., Веснина Л.Э. Взаимосвязи инсулинорезистентности и гиперинсулинемии с маркерами системного воспаления у беременных женщин с ожирением различной степени. Охрана материнства и детства 2014; 2: 48–51/ Tarasenko K.V., Mamontova T.V., Vesnina L.E. Interrelations of insulin resistance and hyperinsulinemia with markers of systemic inflammation in pregnant women with obesity of varying degrees. Protec-tion of motherhood and childhood 2014; 2: 48–51 (in Russian).
  37. Чабанова Н.Б., Матаев С.И., Василькова Т.Н., и соавт. Роль системного воспаления в развитии осложнений беременности у женщин с ожирением. Акушерство и гинекология 2017; 10: 12–8. doi: 10.18565/aig.2017.10.12-18 / Chabanova N.B., Mataev S.I., Va-silkova T.N., et al. The role of systemic inflammation in the development of pregnancy complications in obese women. Akusherstvo i ginekologiya 2017; 10: 12–8. doi: 10.18565/aig.2017.10.12-18 (in Russian).
  38. Cani P.D., Osto M., Geurts L. et al. Involvement of gut microbiota in the development of low-grade infl ammation and type 2 diabetes associated with obesity. Gut microbes. 2012; 3: 279–288.
  39. Сollado M.C., Isolauri E., Laitinen K. et al. Distinct composition of gut microbiota during pregnancy in overweight and normal-weight women. American Journal of Clinical Nutrition 2008; 88: 894–899.
  40. Чабанова Н.Б., Матаев С.И., Василькова Т.Н. и др. Роль системного воспаления в развитии осложнений беременности у женщин с ожирением. Акушерство и гинекология 2017; 10: 12–18 / Chabanova N.B., Ma¬taev S.I., Vasilkova T.N. et al. The role of systemic inflammation in the development of pregnancy complications in obese women. Obstetrics and gynecology 2017; 10: 12–18 (in Russian).
  41. Santangeli L., Sattar N., Huda S.S. Impact of maternal obesity on perinatal and childhood outcomes. Best Pract Res Clin Obstet Gynaecol. 2015; 29 (3): 438–448.
  42. Kautzky-Willer A., Harreiter J., Winhofer-Stöckl Y. et al. Gestations diabetes (GDM) (Update 2019). Wien Klin Wochenschr. 2019; 131 (1): 91–102.
  43. Grieger J.A., Bianco-Miotto T., Grzes-kowiak L.E. et al. Metabolic syndrome in pregnancy and risk for adverse pregnancy outcomes: A prospective cohort of nulliparous women. PLoS Med. 2018; 15 (12): e1002710.
  44. Хромылев А.В. Метаболический синдром и беременность. Ожирение и метаболизм 2014; 2: 3–7 / Khromylev A.V. Metabolic syndrome and pregnancy. Obesity and metabolism 2014; 2: 3–7 (in Russian).
  45. De Souza L.R., Berger H., Retnakaran R. et al. Non-alcoholic fatty liver disease in early pregnancy predicts dysglycemia in mid-pregnancy: prospective study. Am J Gastroenterol. 2016; 111: 665–670. doi: 10.1038/ajg.2016.43
  46. Koralegedara I.S., Warnasekara J.N., Dayaratne K.G. et al. Non-alcoholic fatty liver disease (NAFLD): a signifcant predictor of gestational diabetes mellitus (GDM) and early pregnancy miscarriages–prospective study in Rajarata Pregnancy Cohort (RaPCo). BMJ Open Gastroenterol 2022; 9: e000831
  47. Lee S.M., Kwak S.H., Koo J.N., et al. Non-alcoholic fatty liver disease in the fi rst trimester and subsequent development of gestational diabetes mellitus. Diabetologia. 2019; 62 (2): 238–248.
  48. Hagström H., Höijer J., Ludvigsson J.F. et al. Adverse outcomes of pregnancy in women with non-alcoholic fatty liver disease. Liver Int. 2016; 36 (2): 268–274.
  49. Sarkar M., Djerboua M., Flemming J.A. NAFLD Cirrhosis Is Rising Among Childbearing Women and Is the Most Common Cause of Cirrhosis in Pregnancy. Clin Gastroenterol Hepatol. 2022; 20 (2): e315–e318. doi: 10.1016/j.cgh.2021.01.022.
  50. Sarkar M., Brady C.W., Fleckenstein J. et al. Reproductive Health and Liver Disease: Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology 2021; 73 (1): 318–365. doi: 10.1002/hep.31559.
  51. Shulman G.I. Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease. N Engl J Med. 2014; 371: 1131–1141. DOI: 10.1056/ NEJMra1011035
  52. Zhou M.-S., Schulman I.H., Zeng Q. Link between the reninangiotensin system and insulin resistance: implications for cardiovascular disease. Vasc Med 2012; 17 (5): 330–341
  53. Park M.J., Lee D.H., Joo B.S. et al. Leptin, leptin receptors and hypoxia-induced factor-1α expression in the placental bed of patients with and without preeclampsia during pregnancy. Mol Med Rep. 2018; 17 (4): 5292–5299.
  54. Pérez-Pérez A., Toro A., Vilariño-Garcia T. et al. Leptin action in normal and pathological pregnancies. J Cell Mol Med. 2018; 22 (2): 716–727.
  55. Th agaard I.N., Hedley P.L., Holm J.C. et al. Leptin and Adiponectin as markers for preeclampsia in obese pregnant women, a cohort study. Pregnancy Hypertens 2019; 15: 78–83.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2024 Eco-Vector


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ЭЛ № ФС 77 - 75489 от 05.04.2019 г.